Pricing Log in Create free account
Saturday 17 October 2026 Export HYPD’s income statement to Excel — free account

Hyperion DeFi, Inc.

HYPD Healthcare Biotechnology

Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.84 0.31 −9.84%
Market cap
$49.0M
P/E
0.0×
Fwd P/E
3.6×
Dividend yield
—
F-score
5/9
Altman Z
−8.37
Beneish M
n/a
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.64
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 5 — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.55%

Capital & Financial Ratios $m

Market Cap 48.95
Revenue 1.40
Net Income 6.65
Free Cash Flow (77.17)
Net Debt (1.20)
Current Ratio 2.34 (at or above 1.5: strong)
Debt/Equity 0.08 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 3.60
P/S ratio 28.74 (above 10: high)
P/B ratio 0.39
Past 5Y EPS Growth —
This Y EPS Growth 174.47% (at or above 15%: strong)
Next Y EPS Growth (65.43%) (below 0%: weak)
Next Y revenue growth 182.73% (at or above 10%: strong)
Next 5Y EPS Growth 84.68% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 27.9×, against a ten-year median of 7.6×; over the ten years it ranged from 2.8× in 2022 to 2,212× in 2024.
P/S against its own 10 years 62.43%
10-year low 10-year high
P/B against its own 10 years 3.38%
10-year low 10-year high
EV/Sales against its own 10 years 54.11%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 15 2 6 10
Receivables 0 0 — —
Inventory 0 — — —
Other 0 0 — —
21 3 7 13
2023 2024 2025 Q'26
Payables 2 2 0 0
ST’ Debt — 5 — 3
Other — — — —
10 16 3 6

Compound Annual Growth %

10y 5y 3y
Sales — — (61.27%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 32.85% 21.82% 33.56%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 — 0 0 1
’24 0 0 0 0 0
’23 — — 0 0 0
’21 2 2 — 10 14
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (4) (3) (3) (4) (15)
’24 (10) (8) (6) (6) (30)
’23 (7) (5) (6) (6) (24)
’22 (8) (5) (7) (5) (25)
’21 (5) (5) (5) (6) (21)
’20 (6) (4) (2) 5 (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) 0 — — —
’25 (4) (3) (68) (4) (15)
’24 (10) (8) (6) (6) (30)
’23 (8) (6) (8) (6) (28)
’22 (8) (5) (7) (6) (26)
’21 (5) (6) (6) (6) (22)
’20 (6) (4) (2) 5 (7)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.26 0.92 — — —
’25 (1.59) (2.50) 0.05 (7.76) (9.40)
’24 (18.40) (16.80) (8.80) (15.34) (59.81)
’23 (12.00) (12.80) (14.40) (14.40) (52.80)
’22 (19.20) (17.60) (16.80) (13.60) (66.40)
’21 (16.80) (15.20) (16.80) 8.00 (39.20)
’20 (24.80) (20.00) (18.40) (13.60) (75.20)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 192.00 204.00 88.80 264.80 120.00 84.00 6.16 0.85

Analyst estimates 2026–2028

Powerpack
High — — 859.20 558.64 553.60 617.60 326.40 468.00 205.60 17.18
People
People Employees — 13 24 29 34 45 41 57 14 9
Revenue/emp, $m — 0.00 0.00 0.00 0.06 0.31 0.00 0.00 0.00 0.09
Income, $m
Income, $m Revenue — — — — 2 14 — 0 0 1
Gross margin, % 0.00 0.00 0.00 0.00 60.00 88.57 0.00 (321.05) (6,753.75) 62.72
EBT (4) (5) (17) (21) (20) (13) (28) (27) (50) (45)
EBT margin, % 0.00 0.00 0.00 0.00 (988.50) (91.27) 0.00 (717,397.37) (86,943.11) (5,570.30)
Net income (4) (5) (17) (21) (20) (13) (28) (27) (50) (45)
Depreciation 0 0 0 0 0 0 1 1 2 1
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 7.60 42.54 0.00 0.01 0.07 0.16
Earnings (124.71) (175.20) (145.60) (117.60) (75.20) (39.20) (66.40) (52.80) (59.81) (9.40)
Cash flow (113.20) (161.47) (110.64) (105.46) (24.26) (63.43) (59.69) (46.47) (36.16) (2.95)
Capex (1.52) (0.35) (0.24) (0.93) (0.99) (4.92) (2.08) (7.74) (0.19) 0.00
Free cash flow (114.72) (161.82) (110.88) (106.39) (25.25) (68.35) (61.77) (54.22) (36.35) (2.95)
Book value 106.33 173.74 142.41 65.44 58.15 62.19 40.98 17.55 (15.72) 8.21
Shares, m 0 0 0 0 0 0 0 1 1 5
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 — 0.00 0.00 0.00
P/S — — — — 0.00 6.58 — 6.60 169.80 21.15
P/B — — — — 8.34 5.15 — 8.80 0.00 0.43
EV/Sales — — — — 0.00 6.25 — 6.40 252.79 33.94
EV/FCF — — — — (15.00) (4.45) — (2.88) (0.48) (0.36)
Cash, $m
Cash, $m Operating cash flow (3) (5) (13) (19) (6) (21) (25) (24) (30) (15)
Capex 0 0 0 0 0 (2) (1) (4) 0 —
Free cash flow (3) (5) (13) (19) (7) (22) (26) (28) (30) (15)
Balance, $m
Balance, $m Working capital 3 5 17 11 15 11 23 11 (13) 5
Total debt — — — — 0 7 9 9 5 8
Net debt (3) (5) (20) (14) (28) (12) (14) (6) 3 1
Shareholders’ equity 3 5 17 12 15 20 17 9 (13) 41
Returns, %
Returns, % ROA (113.05) (113.04) (134.48) (121.90) (81.35) (38.98) (89.36) (91.15) (307.07) (169.57)
ROIC 0.00 0.00 0.00 0.00 0.00 (99.54) (574.56) (511.04) 0.00 (68.85)
ROE (130.70) (126.68) (157.09) (147.87) (146.20) (71.45) (148.60) (207.83) 2,432.00 (336.14)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Hyperion DeFi, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LONA LeonaBio, Inc. $49.8M — (loss-making) — — n/m −142.29% (below 0%: shrinking) 0.00% 0.00% Compare
CRBU Caribou Biosciences, Inc. $49.8M — (loss-making) — (loss-making) −43.79% (below 0%: shrinking) n/m −33.16% (below 0%: shrinking) 100.00% (1,690.39%) Compare
MREO Mereo BioPharma Group plc - Sponsored ADR $49.3M — (loss-making) — (loss-making) — n/m +21.02% (above 0%: growing) 0.00% 0.00% Compare
HYPD Hyperion DeFi, Inc. $49.0M — (loss-making) 3.6× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63%
HOWL Werewolf Therapeutics, Inc. $48.5M — (loss-making) — (loss-making) +256.11% (above 0%: growing) n/m +146.46% (above 0%: growing) 100.00% 34.09% Compare
ELTX Elicio Therapeutics, Inc. $48.2M — (loss-making) — (loss-making) −55.27% (below 0%: shrinking) n/m +8.77% (above 0%: growing) 0.00% 0.00% Compare
ACET Adicet Bio, Inc. $48.1M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00% Compare
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $47.6M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $48.3M — — +100.00% — +10.34% 0.00% 0.00%

All 614 Biotechnology stocks →

Hyperion DeFi, Inc. (HYPD) key facts

  • Strength: Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024.
  • Hyperion DeFi, Inc. (HYPD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, HYPD traded at $2.84, a market capitalization of $49.0 million.
  • Return on equity was −336.1% and debt-to-equity 0.08.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −8.37 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Hyperion DeFi, Inc. (HYPD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/HYPD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com